Novartis Int AG allocated business generics and bioanalogues of Sandoz

Moscow, 4 Oct — the PRIME. Novartis Int AG today finished allocation businesses generics and bioanalogues of Sandoz. The stocks Sandoz will begin today auctions at the Swiss stock exchange under SDZ ticker. Director general Novartis Int AG Vas Narasimkhan called this moment "historical". He specified in the statement that Sandoz begins the way with force position as the world leader in the sphere of generics and biosimilar means. Thus the main business Novartis Int AG becomes more dependent now on ability to develop medicines as will lose more reliable source of the income in a type of Sandoz. "After end...